Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, C4 Therapeutics Inc (NASDAQ: CCCC) closed at $6.00 up 1.87% from its previous closing price of $5.89. In other words, the price has increased by $1.87 from its previous closing price. On the day, 0.64 million shares were traded. CCCC stock price reached its highest trading level at $6.27 during the session, while it also had its lowest trading level at $5.91.
Ratios:
For a deeper understanding of C4 Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.09 and its Current Ratio is at 5.09. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.25.
On December 13, 2023, Stifel Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $2 to $12.
Credit Suisse Upgraded its Underperform to Neutral on February 24, 2023, whereas the target price for the stock was revised from $12 to $10.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 18 ’24 when Salter Malcolm bought 13,000 shares for $6.41 per share.
Salter Malcolm bought 8,561 shares of CCCC for $46,061 on Oct 11 ’24.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CCCC now has a Market Capitalization of 418800000 and an Enterprise Value of 220345520. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.16 while its Price-to-Book (P/B) ratio in mrq is 1.67. Its current Enterprise Value per Revenue stands at 7.5 whereas that against EBITDA is -1.921.
Stock Price History:
Over the past 52 weeks, CCCC has reached a high of $11.88, while it has fallen to a 52-week low of $1.06. The 50-Day Moving Average of the stock is -0.91%, while the 200-Day Moving Average is calculated to be -7.38%.
Shares Statistics:
For the past three months, CCCC has traded an average of 977.57K shares per day and 611320 over the past ten days. A total of 60.47M shares are outstanding, with a floating share count of 57.36M. Insiders hold about 17.28% of the company’s shares, while institutions hold 82.39% stake in the company. Shares short for CCCC as of 1728950400 were 6650791 with a Short Ratio of 6.80, compared to 1726185600 on 11923240. Therefore, it implies a Short% of Shares Outstanding of 6650791 and a Short% of Float of 11.66.
Earnings Estimates
The company has 7.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.2 and low estimates of -$0.64.
Analysts are recommending an EPS of between -$1.18 and -$1.7 for the fiscal current year, implying an average EPS of -$1.47. EPS for the following year is -$1.64, with 8.0 analysts recommending between -$1.26 and -$2.36.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for CCCC’s current fiscal year. The highest revenue estimate was $46M, while the lowest revenue estimate was $15M, resulting in an average revenue estimate of $28.43M. In the same quarter a year ago, actual revenue was $20.76M
